SecBot SecBot
8-K ·Filed May 8, 2026

DGX

QUEST DIAGNOSTICS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001104659-26-057938
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight • Neutral

Monitor DGX's leverage ratios and upcoming debt maturities. The 5% coupon is unremarkable for an A-rated issuer. No near-term equity catalyst.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$189.81
T+0 close · May 8, 2026 · via day close
Latest settled
+24.25%
T+60 · $235.84
Vs SPY
+19.86%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 11 $189.81entry
  2. T+1 · 6mo ago +0.19%α +0.33% · $190.18
  3. T+5 · 6mo ago +0.02%α +0.10% · $189.84
  4. T+20 · 5mo ago +7.76%α +8.06% · $204.53
  5. T+60 · 3mo ago +24.25%α +19.86% · $235.84

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Quest Diagnostics issued $500M of 5.000% senior notes due 2036, a routine debt refinancing/capital raise. The notes are senior unsecured obligations and rank equally with existing debt. The filing has no impact on equity fundamentals or operations.

Key Facts

  • Issued $500,000,000 aggregate principal of 5.000% senior notes due 2036.
  • Interest payable semi-annually on June 30 and December 30, starting December 30, 2026.
  • Notes mature on June 30, 2036.
  • Notes are senior unsecured obligations, ranking equally with existing and future senior unsecured debt.
  • Upon a change of control triggering event, holders may require repurchase at 101% of principal plus accrued interest.

Financial Impact

No impact on revenue, earnings, or cash flow. Increases long-term debt by $500M with 5% fixed coupon.

debt

Risk Factors

  • Higher interest expense (approx. $25M annually) could modestly pressure net income.
  • Increased leverage may limit financial flexibility for future acquisitions.

Market Snapshot

Exchange
NYSE
Sector
Services-Medical Laboratories
Analyst Consensus
54% bullish (24 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-057938
Document: tm2613096d2_ex5-1.htm0001104659-26-057938
Document: tm2613096d2_8k.htm0001104659-26-057938
Document: 0001104659-26-057938-index-headers.html0001104659-26-057938
Document: 0001104659-26-057938-index.html0001104659-26-057938
Document: 0001104659-26-057938.txt0001104659-26-057938

US Market Status

Market Closed · Opens Wed (12h 39m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026